EIF5B

Eukaryotic translation initiation factor 5B · O60841 · EIF5B on Sugi Atlas →

332 patent compounds predicted against EIF5B, 258 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tivantinib (SCHEMBL44902)	1.00	1/20
Tivantinib (SCHEMBL44944)	1.00	1/20
Tivantinib (SCHEMBL45306)	1.00	1/20
Tivantinib (SCHEMBL224883)	1.00	1/20
Tivantinib (SCHEMBL1395795)	1.00	1/20
Tivantinib (SCHEMBL2036414)	1.00	1/20
Tivantinib (SCHEMBL12043258)	1.00	1/20
Tivantinib (SCHEMBL14865187)	1.00	1/20
Tivantinib (SCHEMBL29355700)	1.00	1/20
Tivantinib (SCHEMBL2015821)	0.92	1/20
SCHEMBL2344229	0.88	1/20
SCHEMBL3689556	0.88	1/20
SCHEMBL3689562	0.88	1/20
SCHEMBL12449597	0.88	1/20
SCHEMBL12808552	0.88	1/20
SCHEMBL13241026	0.88	1/20
SCHEMBL2879596	0.87	1/20
SCHEMBL2879812	0.87	1/20
SCHEMBL3114656	0.87	1/20
SCHEMBL3120542	0.87	1/20

Clinical trials — most relevant to EIF5B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.	PHASE1/PHASE2	RECRUITING
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)	PHASE2	RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
GADD34 and Type I IFN Response Genes in SLE	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Probiotic-Muscle Study	nan	COMPLETED
Maintenance of Muscle Mass in Older People: the Negative Impact of Statin Therapy	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a EIF5B binder may also engage these)

Protein	Name	Similarity
Q5RDE1	—	1.000	Q5RDE1 →
Q05D44	—	1.000	Q05D44 →
B2GUV7	—	1.000	B2GUV7 →
P39730	—	0.999	P39730 →
Q6PGY5	—	0.995	Q6PGY5 →
Q568K9	—	0.994	Q568K9 →
Q0II91	—	0.994	Q0II91 →
Q2VPH1	—	0.994	Q2VPH1 →
O17966	—	0.994	O17966 →
G0S8G9	—	0.993	G0S8G9 →
P30181	—	0.993	P30181 →
Q9VWD4	—	0.993	Q9VWD4 →
Q00313	—	0.993	Q00313 →
Q10251	—	0.993	Q10251 →
Q54RC3	—	0.993	Q54RC3 →
Q196Z0	—	0.992	Q196Z0 →
E9Q8D0	—	0.992	E9Q8D0 →
Q9LFE0	—	0.992	Q9LFE0 →
B4N0P7	—	0.992	B4N0P7 →
P38806	—	0.992	P38806 →
A2RVJ8	—	0.992	A2RVJ8 →
B4KF66	—	0.992	B4KF66 →
Q9FG73	—	0.992	Q9FG73 →
A3LNR4	—	0.992	A3LNR4 →
Q22472	—	0.992	Q22472 →
Q5F1R6	—	0.992	Q5F1R6 →
Q299F9	—	0.992	Q299F9 →
P0C1J2	—	0.992	P0C1J2 →
Q18691	—	0.992	Q18691 →
Q14692	—	0.992	Q14692 →